{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:55:09Z","timestamp":1761580509417},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1007\/s11912-002-0048-5","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T15:23:46Z","timestamp":1180711426000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Thalidomide: An antineoplastic agent"],"prefix":"10.1007","volume":"4","author":[{"given":"Robert J.","family":"Amato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"48_CR1","first-page":"195","volume-title":"Casarett and Doull\u2019s Toxicology: The Basic Science of Poisons","author":"JM Manson","year":"1986","unstructured":"Manson JM: Teratogens. In Casarett and Doull\u2019s Toxicology: The Basic Science of Poisons, edn 3. Edited by Klassen CD, Amdur MO, Doull J. New York: Macmillan; 1986:195\u2013220.","edition":"edn 3"},{"key":"48_CR2","first-page":"21","volume":"27","author":"GW. Muller","year":"1997","unstructured":"Muller GW.: Thalidomide: from tragedy to new drug discovery. Chemtach. 1997, 27:21\u201325.","journal-title":"Chemtach"},{"key":"48_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.173.3.699","volume":"173","author":"EP Sampaio","year":"1991","unstructured":"Sampaio EP, Sarno EN, Galilly R, et al.: Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. J Exp Med 1991, 173:699\u2013703.","journal-title":"J Exp Med"},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","volume":"6","author":"J Sheskin","year":"1965","unstructured":"Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965, 6:303\u2013306.","journal-title":"Clin Pharmacol Ther"},{"key":"48_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","volume":"35","author":"S Tseng","year":"1996","unstructured":"Tseng S, Pak G, Washenik K, et al.: Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996, 35:969\u2013979.","journal-title":"J Am Acad Dermatol"},{"key":"48_CR6","first-page":"111","volume":"15","author":"GE Somers","year":"1960","unstructured":"Somers GE. Pharmacological properties of thalidomide (alpha-phtalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960, 15:111\u2013116.","journal-title":"Br J Pharmacol"},{"key":"48_CR7","first-page":"35","volume":"56","author":"SM Gad","year":"1985","unstructured":"Gad SM, Shannon EJ, Krotoski WA, et al.: Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. LEPR Rev 1985; 56:35\u201339.","journal-title":"LEPR Rev"},{"key":"48_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0024-3205(94)90099-X","volume":"66","author":"AC Nogueira","year":"1994","unstructured":"Nogueira AC, Neubert R, Helge H, Neubert D: Thalidomide and the immune system: simultaneous up-and down-regulation of different integrin receptors on human white blood cells. Life Sciences 1994, 66:77\u201392.","journal-title":"Life Sciences"},{"key":"48_CR9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/bmj.2.5463.687","volume":"2","author":"K Hellman","year":"1965","unstructured":"Hellman K, Duke DI, Tucker DF: Prolongation of skin homograft survival by thalidomide. BMJ 1965, 2:687\u2013689.","journal-title":"BMJ"},{"key":"48_CR10","first-page":"271","volume":"7","author":"GP Murphy","year":"1970","unstructured":"Murphy GP, Mirand EA, Groenewald JH, et al.: Erythropoietin release in renal allografted baboons, with and without immunosuppression. Invest Urol 1970, 7:271\u2013282.","journal-title":"Invest Urol"},{"key":"48_CR11","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1073\/pnas.90.13.5974","volume":"90","author":"S Makonkaweyoon","year":"1993","unstructured":"Makonkaweyoon S, Limson-Pobre RNR, Moreira AL, et al.: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 1993; 90:5974\u20135978.","journal-title":"Proc Natl Acad Sci USA"},{"key":"48_CR12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/aid.1997.13.1047","volume":"13","author":"P Haslett","year":"1997","unstructured":"Haslett P, Hempstead M, Seidman C, et al.: The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Human Retrovir 1997, 13:1047\u20131054.","journal-title":"AIDS Res Human Retrovir"},{"key":"48_CR13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00042560-199603010-00005","volume":"11","author":"JD Klausner","year":"1996","unstructured":"Klausner JD, Makonkawkeyoon S, Akarasewi P, et al.: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M tuberculosis infection. J Acq Immune Def Syndr Human Retrovir 1996, 11:247\u2013257.","journal-title":"J Acq Immune Def Syndr Human Retrovir"},{"key":"48_CR14","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","volume":"177","author":"AL Moriera","year":"1993","unstructured":"Moriera AL, Sampaio EP, Zmuidznias A, et al.: Thalidomide exerts its uninhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993, 177:1675\u20131680.","journal-title":"J Exp Med"},{"key":"48_CR15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/168.2.408","volume":"68","author":"EP Sampaio","year":"1993","unstructured":"Sampaio EP, Kaplan G. Miranda A, et al.: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993, 68:408\u2013414.","journal-title":"J Infect Dis"},{"key":"48_CR16","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91:4082\u20134085. The effect of thalidomide on growing vessels is observed only when the drug is administered systemically, suggesting the need for formation of an active metabolite in vivo.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"48_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1006\/exer.1997.0292","volume":"64","author":"BM Kenyon","year":"1997","unstructured":"Kenyon BM, Browne F, D\u2019Amato R: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Eye Res 1997, 64:971\u2013978. Thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor.","journal-title":"Eye Res"},{"key":"48_CR18","first-page":"111","volume":"15","author":"GE Somers","year":"1960","unstructured":"Somers GE: Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960, 15:111\u2013116.","journal-title":"Br J Pharmacol"},{"key":"48_CR19","first-page":"402","volume":"17","author":"T-L Chen","year":"1989","unstructured":"Chen T-L, Vogelsang GB, Petty BG, et al.: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing healthy male volunteers. Drug Metab Dispos 1989, 17:402\u2013405.","journal-title":"Drug Metab Dispos"},{"key":"48_CR20","first-page":"352","volume":"25","author":"S Fabro","year":"1965","unstructured":"Fabro S, Schumacher H, Smith RL, et al.: The metabolism of thalidomide: some biological effects of thalidomide and its metabolites. Br J Pharmacol 1965, 25:352\u2013362.","journal-title":"Br J Pharmacol"},{"key":"48_CR21","first-page":"325","volume":"25","author":"H Schumacher","year":"1965","unstructured":"Schumacher H, Smith RL, Williams RT: The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol 1965, 25:325\u2013337.","journal-title":"Br J Pharmacol"},{"key":"48_CR22","first-page":"338","volume":"25","author":"H Schumacher","year":"1965","unstructured":"Schumacher H, Smith RL, Willians T: The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965, 25:338\u2013351.","journal-title":"Br J Pharmacol"},{"key":"48_CR23","first-page":"719","volume":"45","author":"CGS Iyer","year":"1971","unstructured":"Iyer CGS, Languillon J, Ramanujam K, et al.: WHO coordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Org 1971, 45:719\u2013732.","journal-title":"Bull World Health Org"},{"key":"48_CR24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/cpt1970114481","volume":"11","author":"RC Hastings","year":"1970","unstructured":"Hastings RC, Trautman JR, Enna CD, Jacobson RR: Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum. Clin Pharmacol Ther 1970, 11:481\u2013487.","journal-title":"Clin Pharmacol Ther"},{"key":"48_CR25","first-page":"111","volume":"40","author":"JMH Pearson","year":"1969","unstructured":"Pearson JMH, Vedaigiri M: Treatment of moderately severe erythema nodosum leprosum with thalidomide I: a double-blind controlled trial. Lepr Rev 1969, 40:111\u2013116.","journal-title":"Lepr Rev"},{"key":"48_CR26","first-page":"135","volume":"37","author":"J Sheskin","year":"1969","unstructured":"Sheskin J: Further observation with thalidomide in lepra reactions. Lepr Rev 1969, 37:135\u2013146.","journal-title":"Lepr Rev"},{"key":"48_CR27","first-page":"26","volume":"42","author":"MFR Waters","year":"1971","unstructured":"Waters MFR: An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 1971, 42:26\u201342.","journal-title":"Lepr Rev"},{"key":"48_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/aid.1997.13.301","volume":"13","author":"LN Alexander","year":"1997","unstructured":"Alexander LN, Wilcox CM: A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Human Retrovir 1997, 13:301\u2013304.","journal-title":"AIDS Res Human Retrovir"},{"key":"48_CR29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-2007-1005525","volume":"28","author":"D Louvel","year":"1996","unstructured":"Louvel D, Musso S, Metivier S, et al.: Idiopathic esophageal ulceration associated with human immunodeficiency virus infection efficacy of thalidomide treatment. Endoscopy 1996, 28:471\u2013472.","journal-title":"Endoscopy"},{"key":"48_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000246279","volume":"193","author":"JM Bonnetblanc","year":"1996","unstructured":"Bonnetblanc JM, Royer C, Bedane C: Thalidomide and recurrent aphthous stomatitis: a follow-up study. Dermatology 1996, 193:321\u2013323.","journal-title":"Dermatology"},{"key":"48_CR31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/clinids\/23.3.501","volume":"23","author":"RA Soler","year":"1996","unstructured":"Soler RA, Howard M, Brink NS, et al.: Regression of AIDSrelated Kaposi\u2019s sarcoma during therapy with thalidomide. Clin Infect Dis 1996, 23:501\u2013503.","journal-title":"Clin Infect Dis"},{"key":"48_CR32","first-page":"41a","volume":"17","author":"P Politi","year":"1998","unstructured":"Politi P, Reboredo G, Losso M, et al.: Phase I trial of thalidomide (T) in AIDS-related Kaposi sarcoma (KS) [abstract]. Proc ASCO 1998, 17:41a.","journal-title":"Proc ASCO"},{"key":"48_CR33","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","volume":"18","author":"RF Little","year":"2000","unstructured":"Little RF, Wyville KM, Pluda JM, et al.: Activity of thalidomide in AIDS-related Kaposi\u2019s sarcoma. J Clin Oncol 2000, 18:2593\u20132602.","journal-title":"J Clin Oncol"},{"key":"48_CR34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","volume":"18","author":"HA Fine","year":"2000","unstructured":"Fine HA, Figg WD, Jaeckle K, et al.: Phase II trial of the antiangiogenic agent, thalidomide, in patients with recurrent high grade gliomas. J Clin Oncol 2000, 18:708\u2013715. The investigators note that thalidomide is well tolerated and may have some biologic activity in this population.","journal-title":"J Clin Oncol"},{"key":"48_CR35","first-page":"551","volume":"18","author":"J Glass","year":"1999","unstructured":"Glass J, Gruber ML, Nirenberg A: Phase I\/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme [abstract]. Proc ASCO 1999, 18:551.","journal-title":"Proc ASCO"},{"key":"48_CR36","first-page":"333","volume":"16","author":"WD Figg","year":"1997","unstructured":"Figg WD, Bergan R, Brawley O, et al.: Randomized phase II study of thalidomide in androgen-indpendent prostate cancer(AIPC)[abstract]. Proc ASCO 1997, 16:333.","journal-title":"Proc ASCO"},{"issue":"suppl 1","key":"48_CR37","first-page":"318a","volume":"92","author":"S Singhal","year":"1998","unstructured":"Singhal S, Mehta J, Eddlemon P, et al.: Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM) [abstract]. Blood 1998, 92(suppl 1):318a. The authors concluded that thalidomide has remarkable antitumor activity in advanced and high-risk multiple myeloma and should be considered for incorporation into combination trials.","journal-title":"Blood"},{"key":"48_CR38","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.2000.18.14.2710","volume":"18","author":"SM Baidas","year":"2000","unstructured":"Baidas SM, Winer EP, Fleming GF, et al.: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000, 18:2710\u20132717.","journal-title":"J Clin Oncol"},{"key":"48_CR39","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565\u20131571.","journal-title":"N Engl J Med"},{"key":"48_CR40","unstructured":"Desikan R, Munshi N, Zeldis J, et al.: Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. Presented at the American Society of Hematology 41st Annual Meeting. New Orleans, LA December 3\u20137, 1999. (abstract 2685)."},{"key":"48_CR41","unstructured":"Sabir T, Raza S, Anderson L, Jagannath S: Thalidomide is effective in the treatment of recurrent refractory multiple myeloma (MM) [abstract]. Presented at the American Society of Hematology 41st Annual Meeting. December 3\u20137, 1999. New Orleans, LA (abstract 548)."},{"key":"48_CR42","unstructured":"Fonseca R, Dispenzieri A, Lacy MQ, et al.: Thalidomide in the treatment of relapsed and refractory myeloma. Presented at the American Society of Hematology 41st Annual Meeting. December 3\u20137, 1999. New Orleans, LA (abstract 1414)."},{"key":"48_CR43","unstructured":"Schiller G, Vescio R, Berenson J: Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. Presented at the American Society of Hematology 41st Annual Meeting. December 3\u20137, 1999. New Orleans, LA (abstract 1417)."},{"key":"48_CR44","unstructured":"Durie BGM, Stepan DE: Efficacy of low dose thalidomide (T) in multiple myeloma. Presented at the American Society of Hematology 41st Annual Meeting. December 3\u20137, 1999. New Orleans, LA (abstract 1413)."},{"key":"48_CR45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","volume":"82","author":"T Eisen","year":"2000","unstructured":"Eisen T, Boshoff C, Mak I, et al.: Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000, 82:812\u2013817. The authors conclude that further studies using thalidomide at higher doses as a single agent for renal cell cancer and in combination with biochemotherapy regimens are warranted.","journal-title":"Br J Cancer"},{"key":"48_CR46","first-page":"1384","volume":"19","author":"D Minor","year":"2000","unstructured":"Minor D, Elias L: Thalidomide treatment of metastatic renal cell carcinoma [abstract]. Proc ASCO 2000, 19:1384.","journal-title":"Proc ASCO"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-002-0048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-002-0048-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-002-0048-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-002-0048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:51:10Z","timestamp":1659091870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-002-0048-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s11912-002-0048-5","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"56"}}